Noom Med vs Ro 2026: GLP-1 Weight Loss Programs Compared
A detailed comparison of Noom Med and Ro for GLP-1 weight loss treatment. We examine pricing, medication options, coaching models, clinical quality, and overall value — plus how Trimi compares on cost.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This comparison is updated regularly when pricing, medication availability, or provider policies change across Noom Med, Ro, and other GLP-1 platforms.
Quick links: Semaglutide treatment, tirzepatide treatment, and cheapest GLP-1 injections 2026.
More on GLP-1 Provider Comparisons
Noom Med vs Ro for Weight Loss: What You Need to Know
If you are comparing noom vs ro weight loss programs for GLP-1 medication, the decision comes down to whether you value behavioral coaching bundled with your prescription or prefer a streamlined, medication-first approach. Noom Med and Ro are two of the largest telehealth platforms offering semaglutide and tirzepatide for weight management, but their models differ significantly in philosophy, pricing structure, and what patients actually receive for their money.
Definition
Noom Med is the prescription medication arm of the Noom weight loss platform, combining GLP-1 drugs like semaglutide with Noom's app-based behavioral coaching program. Ro (formerly Roman) is a direct-to-consumer telehealth company offering GLP-1 medications through its Body program as part of a broader health platform that also covers sexual health, dermatology, and other conditions.
Both platforms prescribe the same class of medication — GLP-1 receptor agonists — which clinical trials have demonstrated produce meaningful weight loss. The STEP 1 trial showed that semaglutide 2.4 mg produced an average of 14.9% body weight reduction over 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SURMOUNT-1 trial demonstrated that tirzepatide produced up to 22.5% body weight reduction at the highest dose over 72 weeks (Jastreboff et al., NEJM, 2022). These results are achievable regardless of which provider prescribes the medication — the drug does the same work whether it comes from Noom Med, Ro, or any other licensed prescriber.
The practical question for patients is therefore not which provider has better medication — the medication is the same — but which provider offers the best combination of clinical quality, value, and supplementary services for your specific situation. This guide breaks down every meaningful difference to help you decide.
Noom Med vs Ro vs Trimi: Side-by-Side Comparison
The following table compares all three providers across the dimensions that matter most to patients choosing a GLP-1 weight loss program. Pricing reflects publicly available rates as of early 2026 and may change.
| Feature | Noom Med | Ro | Trimi |
|---|---|---|---|
| Semaglutide monthly cost | $149–$209/mo | $99–$199/mo | $99/mo |
| Tirzepatide monthly cost | Varies / limited | $199–$349/mo | $125/mo |
| App/coaching fee | $32–$70/mo additional | None | None |
| All-inclusive pricing | No (med + app separate) | Yes | Yes |
| Flat dose-independent pricing | No | No | Yes |
| Behavioral coaching | App-based (extra cost) | Minimal | Clinical guidance |
| Contract commitment | Varies by plan | Month-to-month | None |
| Provider visits | Included | Included | Included |
| Other health services | Noom app ecosystem | Sexual health, derm, hair loss | GLP-1 focused |
| Cancellation penalties | Varies | None | None |
| 12-month total (semaglutide) | $2,172–$3,348+ | $1,188–$2,388 | $1,188 |
| Best for | Patients wanting behavioral coaching with medication | Patients wanting a broad telehealth platform with GLP-1 | Patients wanting best value for clinical GLP-1 care |
Note: Noom Med's 12-month total includes medication only at the lower end ($149 x 12 = $1,788) and medication plus app at the upper end. Actual costs depend on dose, plan length, and promotional pricing. Ro's range reflects dose-dependent semaglutide pricing. Trimi's flat $99/month is consistent regardless of dose.
Pricing Breakdown: The Real Cost of Each Provider
Understanding the true cost of GLP-1 therapy through each provider requires looking beyond the headline monthly price. Noom Med's pricing structure is more complex than Ro's or Trimi's because the medication subscription and behavioral coaching app are separate products that may be billed independently.
Noom Med Pricing
Noom Med charges approximately $149 to $209 per month for semaglutide, with pricing that can vary based on dose and promotional offers. The Noom behavioral coaching app — which is Noom's original product and the feature that differentiates Noom Med from other prescribers — is a separate subscription that costs approximately $32 to $70 per month depending on plan length. Patients who want the full Noom experience (medication plus app-based coaching) can expect to pay $181 to $279 per month combined. Over 12 months, that totals $2,172 to $3,348 or more.
This split pricing model creates a common point of confusion. Patients who sign up for Noom Med expecting the behavioral coaching to be included may discover it requires an additional subscription. Conversely, existing Noom app subscribers who add medication may not realize the medication cost is on top of their current app fee. Before enrolling, confirm exactly what is and is not included in the quoted price.
Ro Pricing
Ro's weight loss program (Ro Body) charges $99 to $199 per month for semaglutide and $199 to $349 per month for tirzepatide. Pricing is dose-dependent, meaning patients on higher maintenance doses pay more than those on starting doses. Ro's pricing is all-inclusive for the weight loss program — the quoted monthly fee covers the medication, provider consultations, and shipping. There are no separate app fees or coaching charges.
Ro's dose-dependent pricing means that while the starting price is competitive, the monthly cost increases as patients titrate up to therapeutic maintenance doses. A patient who starts at $99 per month on a low semaglutide dose may eventually pay $199 per month at the maintenance dose. Over a full treatment course, this escalation adds significantly to the total cost compared to flat-pricing providers.
Trimi Pricing
Trimi charges $99 per month for semaglutide and $125 per month for tirzepatide. This pricing is flat and dose-independent — patients pay the same amount whether they are on a starting dose or a full maintenance dose. The monthly fee includes the medication, provider consultations, dosage adjustments, and shipping. There are no app fees, enrollment charges, or cancellation penalties.
Annual Cost Comparison
At maintenance doses over 12 months: Noom Med with app costs approximately $2,172 to $3,348. Ro costs approximately $1,188 to $2,388 for semaglutide. Trimi costs $1,188 for semaglutide or $1,500 for tirzepatide. The difference between the most and least expensive option can exceed $2,000 per year — and GLP-1 therapy typically continues for 12 to 24 months or longer. For a complete cost analysis, see our cheapest GLP-1 injections guide.
The Coaching Debate: Is Noom's Behavioral Program Worth the Premium?
The fundamental differentiator between Noom Med and Ro is behavioral coaching. Noom built its reputation on a psychology-based weight loss app before expanding into prescription medication, and the company positions the combination of medication plus behavioral coaching as its competitive advantage. The question for patients is whether that coaching justifies paying $32 to $70 more per month than a medication-only provider.
The clinical argument for combining behavioral therapy with GLP-1 medication has legitimate support. Research demonstrates that behavioral interventions can enhance and sustain weight loss outcomes when paired with pharmacotherapy. Patients who develop better eating habits, exercise routines, and psychological coping strategies during medication use may be better positioned to maintain weight loss if they eventually discontinue the medication. Noom's app uses cognitive behavioral therapy principles, food logging, educational articles, and group coaching to address the behavioral side of weight management.
However, there are important counterpoints. First, Noom's coaching is primarily algorithm-driven and delivered through an app rather than through one-on-one sessions with a clinical psychologist or certified obesity specialist. The level of personalization and clinical depth is not comparable to formal behavioral therapy conducted by a specialist. Second, GLP-1 medications themselves fundamentally alter the behavioral equation by reducing appetite, decreasing food noise, and making it physiologically easier to eat less — which means the behavioral challenges that coaching addresses are already significantly mitigated by the medication. Third, many patients report declining engagement with the Noom app over time while continuing to pay the subscription fee.
For patients who are new to weight management and want structured guidance alongside their medication, Noom's coaching may provide value during the initial months of treatment. For patients who are self-motivated, already knowledgeable about nutrition, or primarily seeking affordable medication access, the coaching premium is difficult to justify — particularly when managing side effects and maintaining treatment are the primary clinical needs rather than behavioral restructuring.
When Noom's Coaching May Be Worth It
You are entirely new to structured weight management and want guided behavioral support
You have a history of emotional or stress-related eating and want CBT-based tools
You plan to use medication temporarily and want to build habits for post-medication maintenance
You enjoy app-based tracking and accountability and will actively engage with the platform
When Coaching May Not Justify the Cost
You already understand nutrition basics and have existing exercise routines
You find the GLP-1 medication sufficiently addresses appetite and food noise
You prefer to allocate your budget entirely toward medication rather than app subscriptions
You have tried the Noom app before and did not find it engaging long-term
Ro's Approach: Medication-Focused Telehealth
Ro (originally launched as Roman for men's health) has evolved into one of the largest direct-to-consumer telehealth platforms in the United States. Unlike Noom, which started as a behavioral weight loss app, Ro built its business around convenient, affordable access to prescription medications across multiple health categories. The weight loss program — Ro Body — is one vertical within a broader platform that also covers sexual health, dermatology, hair loss, and other conditions.
This medication-first philosophy shapes the Ro weight loss experience. Patients complete an online health assessment, consult with a licensed provider, and receive their GLP-1 medication shipped to their door. The process is efficient and streamlined. Ro does not bundle extensive behavioral coaching or require patients to engage with a separate app curriculum. The clinical focus is on medication management: proper dosing, titration schedules, side effect management, and ongoing provider oversight.
For patients who view GLP-1 therapy as a medical treatment rather than a lifestyle program, Ro's approach is straightforward and practical. You get the medication, clinical oversight, and the flexibility to manage your own diet and exercise without paying for coaching services you may not use. The trade-off is that patients who genuinely need structured behavioral support will not find it through Ro's weight loss program.
Ro's broader telehealth platform is a minor advantage for patients who consolidate multiple health needs through a single provider. If you already use Ro for other prescriptions or services, adding weight loss medication to your existing account is convenient. However, this consolidation benefit is marginal — most patients choose their GLP-1 provider based on medication cost and clinical quality rather than whether the platform also sells hair loss treatments.
Clinical Evidence: What the Research Shows
The clinical evidence supporting GLP-1 medications for weight loss is robust and applies equally regardless of which provider prescribes the medication. Understanding this evidence helps patients evaluate whether the supplementary services offered by different providers meaningfully change outcomes, or whether the medication itself drives the majority of results.
Semaglutide: STEP Trial Program
The landmark STEP 1 trial enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity and randomized them to semaglutide 2.4 mg weekly or placebo, both with lifestyle counseling. At 68 weeks, the semaglutide group lost an average of 14.9% of body weight compared to 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). Notably, both groups received the same lifestyle counseling — the difference in outcomes was driven by the medication, not the counseling alone.
The STEP 3 trial specifically tested semaglutide combined with intensive behavioral therapy (26 individual counseling sessions over 68 weeks) and found that adding intensive behavioral therapy to semaglutide produced modestly greater weight loss than semaglutide with standard counseling. This suggests that behavioral support provides incremental benefit, but the medication remains the primary driver of weight loss outcomes.
Tirzepatide: SURMOUNT Trial Program
The SURMOUNT-1 trial demonstrated even greater weight loss with tirzepatide. Among 2,539 adults with obesity, tirzepatide at the highest dose (15 mg) produced an average weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo (Jastreboff et al., New England Journal of Medicine, 2022). Tirzepatide's dual GIP/GLP-1 receptor agonism appears to produce superior weight loss compared to semaglutide's GLP-1-only mechanism. Both Ro and Trimi offer tirzepatide, while Noom Med's tirzepatide availability has been more limited.
The critical insight from these trials is that GLP-1 medications produce substantial weight loss with standard lifestyle counseling — the type of basic clinical guidance that all three providers (Noom Med, Ro, and Trimi) include in their programs. While intensive behavioral therapy can provide incremental benefit, the magnitude of that additional benefit is modest compared to the medication effect. Patients should weigh whether a small incremental improvement in outcomes justifies paying hundreds or thousands of dollars more per year in coaching fees. For more on how these medications work and their side effect profiles, see our clinical guides on semaglutide and tirzepatide.
Noom Med: Strengths and Limitations
Noom Med Strengths
Behavioral coaching app uses CBT-based principles to address psychological aspects of eating
Established brand with a large user community and years of weight loss app development
Structured curriculum and food logging tools provide accountability for patients who need external structure
Combination of medication and behavioral support aligns with clinical best practices for obesity treatment
Noom Med Limitations
Split pricing between medication and app creates confusion and increases total cost significantly
Semaglutide pricing ($149–$209/mo) is higher than Ro's lower tier and substantially higher than Trimi
App coaching is algorithm-driven rather than delivered by certified obesity specialists
Many users report declining engagement with the app over time while continuing to pay the subscription
Tirzepatide availability has been more limited compared to competitors that offer both medications broadly
Cancellation policies for the app subscription have historically drawn consumer complaints
Ro: Strengths and Limitations
Ro Strengths
All-inclusive pricing — no separate app fees or hidden charges beyond the quoted monthly rate
Offers both semaglutide and tirzepatide with broad availability
Established telehealth infrastructure with efficient intake and medication delivery
Month-to-month commitment with no cancellation penalties
Broader health platform allows consolidation of multiple prescriptions through one provider
Ro Limitations
Dose-dependent pricing means costs increase as patients titrate to maintenance doses
Minimal behavioral coaching or structured support beyond medication management
Semaglutide can reach $199/mo at higher doses — significantly more than Trimi's flat $99/mo
Tirzepatide at $199–$349/mo is substantially more expensive than Trimi's $125/mo
Weight loss is one of many verticals rather than the company's core focus
The Bottom Line: Which Provider Should You Choose?
The choice between Noom Med, Ro, and Trimi depends on what you prioritize in a GLP-1 weight loss program. All three are legitimate providers with licensed clinicians, genuine medication, and functional treatment programs. The differences are in pricing, supplementary services, and overall value proposition.
Choose Noom Med if behavioral coaching is essential to you
Noom Med makes sense for patients who specifically want structured, app-based behavioral coaching alongside their GLP-1 medication and are willing to pay a premium for it. Be aware that the coaching app is typically an additional subscription on top of medication costs. Noom Med is the most expensive option in this comparison, but the behavioral tools are unique among the three providers.
Choose Ro if you want a broad telehealth platform with straightforward medication access
Ro is a reasonable choice for patients who want efficient GLP-1 prescribing within a larger telehealth ecosystem and do not need behavioral coaching. Ro's all-inclusive pricing is simpler than Noom Med's split model, but dose-dependent pricing means costs escalate at higher doses. Ro is particularly convenient if you already use the platform for other health needs.
Choose Trimi for the best value in clinical GLP-1 care
Trimi offers the lowest price for both semaglutide ($99/mo) and tirzepatide ($125/mo) with flat, dose-independent pricing, no contracts, and no hidden fees. For the majority of patients who need effective medication with competent clinical oversight at a sustainable price, Trimi delivers the best value. The savings over Noom Med and Ro compound significantly over the 12 to 24 months of typical GLP-1 treatment.
If you are currently on Noom Med or Ro and considering a switch, our step-by-step guides walk you through the process: how to cancel Noom Med and switch providers and how to cancel Ro and switch providers. Switching is straightforward and does not require restarting your medication from scratch — your new provider can continue your current dose and titration schedule without interruption.
Frequently Asked Questions
Is Noom Med or Ro cheaper for semaglutide?
Ro is generally cheaper than Noom Med for semaglutide. Ro charges $99 to $199 per month for semaglutide, while Noom Med charges $149 to $209 per month for the medication component alone, with an optional app subscription adding $32 to $70 per month on top. Trimi offers the lowest price at $99 per month for semaglutide with all services included and no additional app fees.
Does Noom Med include the Noom app?
Noom Med's GLP-1 medication subscription does not always include full access to the Noom behavioral coaching app. The app subscription may be a separate charge ranging from approximately $32 to $70 per month depending on the plan length. Some promotional bundles may combine medication and app access, but patients should verify current pricing and what is included before enrolling. The medication program and the app are distinct products within the Noom ecosystem.
Can I get tirzepatide through Noom Med or Ro?
Ro offers tirzepatide at $199 to $349 per month. Noom Med has historically focused more on semaglutide, though tirzepatide availability may vary. Trimi offers tirzepatide at $125 per month with flat pricing regardless of dose. For patients specifically seeking tirzepatide, verify current availability directly with each provider, as medication offerings evolve.
Does Ro offer any behavioral coaching?
Ro's weight loss program is primarily medication-focused. While Ro provides clinical consultations and some educational resources, it does not offer the structured behavioral coaching curriculum that Noom Med bundles (at additional cost) through the Noom app. Ro's broader telehealth platform covers other health areas including sexual health and hair loss, but the weight loss program centers on medication management rather than behavioral intervention.
Is Noom's behavioral coaching worth the extra cost?
The value of Noom's behavioral coaching depends on your individual needs. Clinical research supports combining behavioral therapy with GLP-1 medication for weight loss. However, the Noom app's coaching is delivered through an algorithm-driven platform rather than one-on-one sessions with a specialist. Many patients find that the GLP-1 medication itself significantly reduces the behavioral challenges around eating, making intensive coaching less necessary than it would be without medication. Patients who are self-motivated or already knowledgeable about nutrition may not find the additional $32 to $70 per month worthwhile.
Can I switch from Noom Med or Ro to Trimi?
Yes, switching from either Noom Med or Ro to Trimi is straightforward. Complete Trimi's online health assessment, share your current medication and dose, and a Trimi provider will evaluate whether to continue your current treatment. There is no gap in medication coverage when switching between providers. Many patients switch to Trimi specifically to reduce their monthly costs while maintaining the same GLP-1 therapy. See our guides on switching from Noom Med and switching from Ro for step-by-step instructions.
Which provider has the best medical oversight?
All three providers — Noom Med, Ro, and Trimi — employ licensed healthcare providers for prescribing and medication management. Ro and Trimi use board-certified physicians and nurse practitioners for clinical consultations. Noom Med similarly uses licensed prescribers for its medication program. The quality of clinical oversight is comparable across all three platforms. The meaningful differences are in supplementary services (coaching, app features) and pricing, not in the competence of the prescribing clinicians.
Sources & References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021;384(11):989-1002 (STEP 1 trial).
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022;387(3):205-216 (SURMOUNT-1 trial).
- Wadden TA, et al. "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial." JAMA, 2021;325(14):1403-1413.
- Noom Med. Official pricing and program information. 2026.
- Ro Health. Official pricing and program information. 2026.
- FDA guidance on compounding and the FDA: questions and answers.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Pricing and availability information is approximate and subject to change — verify current rates directly with each provider. Trimi is a competing provider; this comparison is presented fairly but readers should verify current pricing and program details independently.